There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aurinia Pharmaceuticals (AUPH) and Oragenics Inc (OGEN) with bullish sentiments.
Aurinia Pharmaceuticals (AUPH)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Aurinia Pharmaceuticals, with a price target of $15. The company’s shares closed yesterday at $6.07.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 9.7% and a 37.8% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Arcturus Therapeutics Ltd, and Melinta Therapeutics Inc.
Currently, the analyst consensus on Aurinia Pharmaceuticals is a Strong Buy with an average price target of $15.
See today’s analyst top recommended stocks >>
Oragenics Inc (OGEN)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Oragenics Inc today and set a price target of $2. The company’s shares closed yesterday at $0.48, close to its 52-week low of $0.38.
Selvaraju said:
“Our 12-month price target is derived from an estimated market value of the firm at $88M, which includes a DCF analysis based asset value for AG013, with a 18% discount rate and 2% terminal growth rate, excluding debt and assuming 46M shares outstanding at the end of 1Q20.”
According to TipRanks.com, Selvaraju is a 1-star analyst with an average return of -1.7% and a 33.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on Oragenics Inc is a Moderate Buy with an average price target of $2.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
